Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telacebec in moderate COVID-19
NCT04847583Phase 2Terminated
- Sponsor
- Qurient Co., Ltd.
- Start
- Jul 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Telacebec in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Qurient Co., Ltd. Primary endpoint: Biomarker change at Day 14. Started Jul 2021; status: terminated.
02
Drugs
Telacebec
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04847583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04847583.